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Patients with cardiogenic shock who require
mechanical circulation support may profit
from more effective, less invasive devices. Panel
A shows the first-in-man use of biventricular
percutaneous support with impeller devices
(Abiomed Impella, Danvers, MA, USA). The
54-year-old patient presented with acute myocar-
dial infarction and shock due to biventricular pump
failure.When angioplasty of the RCA, intravascular
volume optimization, and high-dose inotropes
failed to stabilize the patient, a percutaneous left
ventricular-assist devicewas implanted. Pulmonary
oedema resolved, but severe right heart failure
with multi-organ failure (liver, kidney) persisted
despite nitric oxide therapy. Additional percutan-
eous device implantation in the right heart led
to circulatory stabilization and progressive organ
function recovery, with successful device weaning
on Day 8. Echocardiography on Day 44 showed
a normal right ventricular function. Panel B
shows the pump head and Panel C the topology of the devices.
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